Early-stage IP decisions in life sciences often occur under pressure but carry long-term implications for licensing, valuation, and portfolio flexibility. This article explores how early patent strategy shapes commercialization outcomes.

As billions in drug patents expire, the pharmaceutical industry faces a looming patent cliff. Biotech innovators must rethink IP protection to safeguard revenue and innovation. This article explores trade secrets, continuous filings, data ownership, and regulatory exclusivity, strategies that help companies adapt and thrive beyond patent loss.